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Iron is essential due to its vital role as a metalloprotein cofactor in numerous 
metabolic and physiological functions. Iron homeostasis is highly regulated at both the 
cellular and systemic levels, which is required for overall organismal well-being. 
Phagocytosing macrophages are critical to systemic iron homeostasis owing to their 
capability to recycle iron from senescent red blood cells, as well as storing iron under 
systemic distress. Ferritin, the cytosolic iron storage protein, and its regulation is 
imperative to the macrophages ability to perform these functions. Nuclear receptor co-
activator 4 (NCOA4) has recently been identified as a key regulator of ferritin, mediating 
its degradation via ferritinophagy. Yet, its function in macrophages remains unclear. The 
present studies employed a cell culture model, J774 murine macrophages, to examine 
the role and regulation of macrophage NCOA4 by iron status, red cell iron recycling, and 
inflammation. By iron supplementation or iron chelation we found that macrophage 
NCOA4 is post-transcriptionally regulated by iron status, which is inversely related to 
ferritin abundance. The loss of NCOA4 impaired ferritin turnover which led to a reduction 
in viable cells in iron deprived conditions. To recapitulate erythrophagocytosis (EP) and 
red cell iron recycling macrophages were treated with opsonized erythrocytes. By EP, 
ferritin iron storage acts as a transition between heme iron and recycling of elemental 
iron by ferroportin. Ferritin abundance peaks at 12 h with a subsequent decrease at 24 h 
which is NCOA4-dependent. To simulate iron overload and inflammatory conditions, 
macrophages were treated with a minihepcidin analog, PR73. Hepcidin activity 
repressed NCOA4 protein leading to an accumulation of ferritin in basal macrophages, 
while preventing the turnover of ferritin between 12 and 24 h in erythrocyte laden 
macrophages. As a model of endotoxemia, macrophages were treated with 
lipopolysaccharide (LPS), which decreased both NCOA4 transcript and protein 
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abundance. This effect on the transcript level was confirmed in vivo, with Ncoa4 mRNA 
abundance repressed in the spleens of mice treated with LPS, a tissue rich with 
phagocytosing macrophages. Altogether our studies demonstrate an active role of 
NCOA4-mediated ferritinophagy in macrophage iron homeostasis. The response of 
NCOA4 to hepcidin and LPS suggests systemic implications and thus may become a 
potential therapeutic target for treatments of iron disorders and anemia of chronic 
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Iron is essential to nearly all living organisms due to the array of biological 
functions it is involved in, such as DNA replication, electron transfer, and heme 
biosynthesis. However, due to iron’s redox reactivity, free iron can cause oxidative stress 
through the production of reactive oxygen species (ROS) via the Fenton reaction. Thus, 
cells possess sophisticated and complex regulatory systems to maintain cellular iron 
demands while also limiting accumulation and oxidative damage.  
Iron functions in the cells and the body primarily in three forms – elemental (ionic) 
iron, heme, and iron-sulfur clusters. The cytosolic labile iron pool provides metabolically 
available iron atoms that become available to metalloproteins or transported to cellular 
compartments where the metal is in need. A class of iron chaperone proteins, poly-r(C) 
binding proteins (PCBPs), mediates the distribution of exchangeable cytosolic iron to 
iron-dependent enzymes and into ferritin, a protein of cellular iron storage.1,2  Heme, a 
protoporphyrin ring with an iron atom coordinated at its center, is a multi-functional 
metalloprotein owing to its capability to participate in oxygenation and redox reactions. In 
mammals, the majority of heme in the body functions as an oxygen carrier as a 
component of hemoglobin in red blood cells and myoglobin in muscle tissue. Heme also 
serves as a prosthetic group of hemoproteins, such as cytochrome c, and thus is critical 
in energy metabolism.3 Similar to heme, iron-sulfur clusters act as prosthetic groups in 
numerous metalloproteins to serve as electron donors-acceptors in oxidation-reduction 
reactions.  
Elemental iron is required for optimal metabolic functioning, yet too much can be 
detrimental. Free, unbound iron is redox active, which leads to the production of hydroxy 
2 
 
radicals (·OH) by the Fenton reaction. The hydroxy radicals can then react with DNA, 
proteins, phospholipids, and other biomolecules causing cellular damage. Therefore, 
cellular iron homeostasis is tightly regulated.  
Cellular Iron Homeostasis 
To maintain cellular iron requirements cells take up transferrin bound iron 
through a transferrin receptor-mediated mechanism.4,5 Transferrin (Tf) functions as an 
iron courier in the blood circulatory system, transporting and distributing redox inactive 
ferric (Fe3+) iron throughout the body for utilization.6,7 Tf-bound iron is taken up by the 
cell through the interaction of holo-Tf (diferric) with transferrin receptor 1 (TfR1) on the 
plasma membrane. This interaction initiates the internalization of the Tf-TfR1 complex by 
clathrin-mediated endocytosis.8 Within the endosome a drop in the pH creates an acidic 
environment, resulting in the dissociation of ferric iron from Tf.9,10 Metalloreductases, 
such as six transmembrane epithelial antigen of the prostate 3 (STEAP3), reduce ferric 
iron to ferrous iron, which is then transported to the cytosol by divalent metal transporter 
1 (DMT1) and incorporated into the labile iron pool.11,12 The remaining endosome 
containing the apo-Tf/TfR1 complex is transported back to the plasma membrane where 
apo-Tf dissociates, back into circulation.13  
Cells can also obtain iron through methods separate from transferrin receptor-
mediated endocytosis. Recent studies have identified the uptake of non-transferrin 
bound iron (NTBI) by several Zrt/Irt-like protein (ZIP) members, ZIP14 and ZIP8. Both 
ZIP14 and ZIP8 import ferrous iron, which can be immediately incorporated into the 
labile iron pool.14–16  
Due to its potential cytotoxicity, labile iron is designated for utilization, storage, or 
export based on the iron requirements of the cell. In the cytosol iron can be utilized by 
3 
 
iron-dependent proteins or trafficked directly to organelles such as the mitochondria to 
be incorporated into heme or iron-sulfur clusters.17 Assisting the trafficking of iron is the 
previously mentioned family of PCBPs, which have demonstrated iron chaperone activity 
within the cytosol, facilitating the distribution of ferrous iron.18,19 For example, both 
PCBP1 and 2 have been shown to be required for the metalation of several iron-
dependent enzymes regulating hypoxia-inducible factor (HIF) and cell proliferation.20,21                                                                                                                                                             
Iron that is not immediately utilized for metabolic purposes can be stored within 
the sole cytosolic iron storage protein, ferritin. Elemental iron is sequestered within 
ferritin in its nontoxic ferric state with each ferritin core accommodating up to 4,500 iron 
atoms. Expression of ferritin increases with rising intracellular iron levels.22,23 Thus, 
ferritin provides two roles for the cell; during iron excess it protects the cell from iron 
toxicity, and serves as a reservoir when iron is required. The ferritin complex is a 24-
subunit multimer consisting of two isoforms – ferritin heavy (FTH1) and light (FTL) 
chains. The expression and ratio of FTH1 and FTL that make up the protein shell varies 
by tissue type and physiological status.24,25 Importantly, FTH1 possesses ferroxidase 
activity (Fe2+ to Fe3+) which enables iron to be incorporated into its iron core.26–28 
Additionally, the metalation of ferritin has been shown to require the iron chaperone 
protein, PCBP1. In vivo and in vitro experiments have demonstrated a protein-protein 
interaction between PCBP1 and ferritin, facilitating metalation of the ferritin complex.1,29 
Furthermore, PCBP1 has been shown to regulate iron storage in developing erythroid 
cells, with microcytic anemia developing in Pcbp1-deficient mice.30 The iron stored within 
ferritin is metabolically unavailable until the ferritin complex is degraded, which will be 
discussed in more detail in subsequent sections. Ultimately, the cells ability to store iron 
within ferritin is vital to the maintenance of cellular iron homeostasis. 
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Lastly, to maintain cellular iron homeostasis cells can export elemental iron 
through the only known mammalian cellular iron exporter, ferroportin (FPN1).31–33 FPN1 
activity can aid in the prevention of iron toxicity when intracellular iron levels rise beyond 
what the cell can handle. Additionally, flux of iron by FPN1 from duodenal enterocytes, 
hepatocytes, and macrophages is necessary to maintain systemic iron homeostasis.34–36 
Therefore, FPN1 possesses multi-level regulation owing to its vital role in cellular and 
systemic iron homeostasis, which will be described in more detail in the following 
sections. The structure of FPN1 and the mechanism by which it exports iron remains an 
area of intense research. Studies hypothesize that FPN1 consists of two transmembrane 
lobes that form a cavity for Fe2+ binding. It is believed that the Fe2+ binding causes a 
conformational shift of the two lobes from an inward (intracellular facing) to outward 
(extracellular facing) conformation, leading to the export of iron.37–40 Ferroxidases in the 
extracellular space oxidize Fe2+ to Fe3+ which can then be bound and transported by 
Tf.41,42 One study has reported that the iron chaperone PCBP2 interacts with FPN1, 
facilitating the export of iron. However, further studies are needed to confirm this 
finding.43  
Mechanisms Regulating the Cellular Iron Pool 
Cellular iron homeostasis is a tightly regulated and coordinated process between 
uptake, storage, export, and utilization. Central to the balance of these processes is the 
iron-responsive element/iron regulatory protein (IRE/IRP) system, which post-
transcriptionally regulates the expression of multiple iron genes. The iron-dependent 
process is regulated by the binding of IRP1 (also functions as the cytosolic isoform of 
aconitase) or IRP2 to stem-loop structures, termed IREs, in the untranslated regions 
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(UTR) of messenger RNA (mRNA) transcripts. The binding activity of IRPs to IREs is 
high when cells are iron-deficient and low in iron-replete conditions.44  
 IREs can be present in the 5’- or 3’-UTR of the mRNA transcript. Transcripts with 
IREs located in the 3’-UTR, such as in TfR1, are stabilized by the binding of IRPs when 
the cell is iron-deficient, promoting translation of the protein and iron uptake by the cell. 
However, when iron levels increase IRPs dissociate from the IRE and the mRNA 
transcript is vulnerable to endonucleases, leading to translational repression.45–47 Ferritin 
(FTH1 and FTL) and FPN1 mRNA contain an IRE in the 5’-UTR. Cellular iron deficiency 
and IRP binding in the 5’-UTR leads to a translational block, reducing ferritin and FPN1 
expression and thus limiting iron storage and export. When iron levels are replete IRPs 
dissociate from the IRE and permit translation of the proteins promoting storage and 
export (Figure 1.1).31,48–50  
 The IRE/IRP system is not the only form of regulation for genes such as TfR1, 
ferritins, and FPN1, however the post-transcriptional nature of the mechanism is what 
makes it physiologically essential. As mentioned, excess intracellular iron can be 
cytotoxic due to ROS production by the Fenton reaction. Therefore, the IRE/IRP system 
provides a quick response to adapt to changes in intracellular iron to maintain 
homeostasis.  
Another mechanism regulating intracellular iron homeostasis is the selective 
degradation of ferritin via a process termed ferritinophagy. When cells become iron 
deficient nuclear receptor coactivator 4 (NCOA4) acts as a selective cargo carrier 
receptor, mediating the delivery of ferritin to the autophagosome. This involves physical 
interaction and complex formation between NCOA4 and ferritin, particularly with its 
ferritin H units.51,52 Fusion of the autophagosome with the lysosome leads to the 
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formation of the autophagolysosome and digestion of the contents by lysosomal 
enzymes. This results in the release of the ferritin iron core and an increase of 
bioavailable iron that can be utilized by the cell.51–53  
The flux of iron through ferritinophagy is mediated by NCOA4 levels. NCOA4 
protein abundance and activity is regulated by intracellular iron levels. Unlike other iron-
regulatory genes such as FPN1, TfR1, and ferritin, the Ncoa4 transcript does not contain 
an IRE in either the 5’- or 3’-UTRs. Instead, NCOA4 is post-translationally regulated by 
the activities of HERC2, an E3 ubiquitin ligase. When cellular iron is sufficient, NCOA4-
HERC2 binding leads to ubiquitination and proteasomal degradation of NCOA4. This 
would limit ferritinophagy and promote iron storage within ferritin. Conversely, when 
cellular iron is deficient, NCOA4-HERC2 binding is reduced, stabilizing NCOA4 for 
enhanced NCOA4-mediated ferritinophagy (Figure 1.2).51  
Systemic Iron Homeostasis at the Organismal Level 
Iron is essential for every cell and tissue in the body; however, the bulk of our 
daily iron requirement is destined for the bone marrow for the development of new red 
blood cells (erythropoiesis). Each day nearly 200 billion red blood cells are produced, 
requiring roughly 20 to 25 mg of iron.54 Systemic iron levels are maintained by dietary 
absorption, tissue iron stores, and recycling of senescent red blood cells by 
macrophages of the reticuloendothelial (RE) system. Systemic iron homeostasis 
requires the same level of intricacy and precision as cellular iron metabolism to sustain 
optimal tissue and organismal functioning. 
Dietary iron is absorbed by duodenal enterocytes. Forms of dietary iron include 
heme and non-heme sources. Heme iron is generally considered more readily absorbed, 
however the mechanism of how this occurs remains unknown. Conversely, details 
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regarding non-heme iron absorption are more understood. Within the lumen of the 
intestine duodenal cytochrome B reduces ferric iron to ferrous iron, allowing it to be 
transported across the apical membrane by DMT1.55–57 Enterocyte iron can be utilized, 
stored, or exported, depending on the iron requirements of the body. FPN1 on the 
basolateral membrane mediates the export of iron from the cell, where hephaestin 
oxidizes Fe2+ to Fe3+ which can then bind and be transported by Tf.32,33,58  
Iron transport through absorptive enterocytes has been shown to be controlled at 
both the apical and basolateral membranes.59 DMT1 expression at the apical surface of 
enterocytes is reduced by iron overload conditions, limiting the amount of non-heme iron 
being absorbed from intake.60 On the basolateral membrane, FPN1 activity and 
expression is repressed by hepcidin, which in turn limits the amount of iron exported 
from the enterocyte into circulation.61,62 These responses of enterocyte DMT1 and FPN1 
mediates adaptation to changes in dietary or body iron status.  
There is no known mechanism for regulated iron excretion. Small amounts of iron 
are lost by exfoliation of epithelial and intestinal cells; however, this is generally 
replenished by dietary iron absorption.63  
The body’s capability to store iron is a crucial component of systemic iron 
homeostasis. Central to iron storage is the liver, which performs three major functions to 
maintain systemic iron balance: sequestering and storing excess iron from the plasma, 
mobilization of iron stores to meet physiological demands, and synthesizing proteins 
integral to systemic iron homeostasis. Hepatocytes function as the major storage site of 
excess iron. When plasma iron levels increase Tf-bound iron is taken up by TfR1-
mediated endocytosis.64 Additionally, in iron overload conditions ZIP14 and DMT1 have 
been shown to be involved in the uptake of non-Tf-bound iron (NTBI) by the liver.15,65–67 
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Conversely, when iron is deficient or demands are increased, iron is mobilized and 
exported by FPN1 into circulation.68  
The liver also functions as the primary location for the synthesis of Tf and 
hepcidin.69,70 Hepcidin is the master regulator of systemic iron, controlling the amount of 
iron being exported into the plasma by FPN1 expressing cells. Hepcidin expression is 
tightly controlled by numerous factors such as inflammation, iron status, and hypoxia 
(discussed in more detail in the subsequent section).71 Tf, in the blood serum, serves not 
only as the iron carrier of the body, but also as a buffering system to limit the amount of 
toxic, free iron in circulation. In normal conditions, roughly 30% of transferrin is saturated 
with iron, offering a sizable buffering capacity for handling increases in plasma iron 
levels.72  
Macrophages of the RE system also contribute to the iron storage capacity of the 
body, however their main function and contribution to systemic iron homeostasis is the 
recycling of iron from effete red blood cells (RBCs). RE macrophages are a group of 
specialized phagocytic cells that originate as monocytes in the bone marrow. This 
includes central nurse macrophages in the bone marrow, Kupffer cells in the liver, and 
red pulp macrophages in the spleen. The spleen is regarded as the main site of iron 
recycling under normal conditions, however the liver has been shown to be important in 
RBC clearance during conditions of increased RBC turnover.73–75 Together, iron recycled 
by RE macrophages provides over 90% of the 20 to 25 mg of iron required for new RBC 
production (adult human).54 The ability to recycle iron is of the utmost importance due to 
the insufficient supply of iron coming from the diet.  
RE macrophages recognize senescent or damaged RBCs by markers present on 
the red cells which promotes their uptake via phagocytosis. Lysosomal fusion with the 
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RBC-phagosome forms the phagolysosome, resulting red cell degradation into various 
components and heme.76 Heme is then transported from the phagolysosome to the 
cytosol by heme-responsive gene 1 (HRG1) and degraded by heme-oxygenase 1 (HO1) 
into carbon monoxide, biliverdin, and iron.77–79 Iron liberated from heme is incorporated 
into the labile iron pool where it can be utilized by the cell, stored within ferritin, or 
exported by FPN1. How iron transiently stored within ferritin is released or regulated in 
this process remains unknown.  
Regulation of the Systemic Iron Pool 
Central to systemic iron homeostasis is the peptide hormone hepcidin, which is 
encoded by the HAMP gene. Hepcidin is predominantly synthesized and released by 
hepatocytes of the liver.70,80 It exerts its function on the only known mammalian cellular 
iron exporter, FPN1 (SLC40A1), regulating the amount of iron circulating in the plasma. 
This is accomplished through posttranslational regulation of FPN1.81 Systemic iron 
homeostasis is maintained by FPN1 expression on three main cell types that export iron 
to the blood circulatory system – hepatocytes (body iron stores), duodenal enterocytes 
(dietary iron), and macrophages of the reticuloendothelial system (iron recycled from 
effete red cells).31–33 Circulating hepcidin binds to FPN1 resulting in the ubiquitination of 
the transmembrane protein, causing its internalization via endocytosis and subsequent 
lysosomal degradation.81,82 More recent studies have shown that hepcidin binding could 
also obstruct the export of iron from FPN1 without causing its internalization and 
degradation.83  
Hepcidin expression is tightly regulated through transcription, responding to 
stimuli such as iron status (iron stores and plasma iron), inflammation, and 
erythropoiesis.84 Each has its own unique molecular mechanism(s) to regulate hepcidin 
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transcription. Nutritional immunity (discussed more in the subsequent section) is the 
result of inflammatory cytokines stimulating hepcidin production, reducing dietary uptake 
of iron from duodenal enterocytes and sequestering iron within iron recycling 
macrophages and hepatocytes, consequently causing hypoferremia.85,86 Under this 
condition hepcidin is stimulated predominantly by the cytokine interleukin 6 (IL-6), which 
is produced in response to inflammation or infection. The loss of IL-6 in mice treated with 
an inflammatory stimulus did not exhibit an increase in hepcidin expression or decrease 
in serum iron compared to stimulated controls. Additionally, this was demonstrated in 
human subjects injected with IL-6, exhibiting increased urinary hepcidin concentrations 
and reduced serum iron.85 Studies have also demonstrated hepcidin induction by other 
cytokines such as IL-1β and IL-22, but their roles in vivo require further investigation.87,88  
Hepcidin induction also occurs through an iron-sensing pathway. This requires 
bone morphogenic protein (BMP) signaling, which phosphorylates SMAD proteins, 
forming a complex that will be translocated into the nucleus where it can bind one of two 
response elements on the promoter of the HAMP gene, thus increasing transcription and 
expression of hepcidin.89–91  
Consistently elevated levels of hepcidin, seen in iron overload and chronic 
inflammatory conditions, will severely limit the amount of iron entering the bloodstream 
to supply erythropoietic needs.92,93 Conversely, elevated erythropoietic needs, e.g., by 
anemia, represses hepcidin expression via activation of the erythropoietin (EPO)-
erythroferrone (ERFE) regulatory axis. Hypoxic signals produced by anemia induces the 
expression of erythropoietin (EPO) in the kidneys and liver.94–96 EPO targets developing 
erythroblasts where ERFE becomes activated. ERFE is a hormone that directly acts on 
hepatocytes, suppressing hepcidin expression.97 Erfe-deficient mice treated with an 
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inflammatory stimulus develop a more pronounced anemia with elevated hepcidin 
mRNA expression, lower serum iron, and delayed tissue iron mobilization compared to 
wild-type controls.98 A decrease in hepcidin permits the mobilization of iron from liver 
stores and iron recycling macrophages, as well as increases the absorption of dietary 
iron. The efflux of iron increases plasma iron levels and provides the iron necessary for 
heme and hemoglobin synthesis in developing red blood cells.98 The molecular 
mechanisms demonstrating how ERFE suppresses hepcidin expression are still being 
studied, but recent in vitro studies have shown that ERFE disrupts several of the BMPs 
that induce hepcidin expression through the BMP-SMAD pathway.99 Altogether, these 
findings highlight the complexity of hepcidin regulation and its vital role in iron 
metabolism. 
Disorders Resulting from Iron Dyshomeostasis 
Organismal iron dyshomeostasis in humans is associated with a number of 
diseases and disorders. The most prevalent iron-related disorder is iron deficiency 
anemia, which affects billions of people worldwide.100 Insufficient iron supply to 
developing red cells impairs hemoglobinization which leads to the formation of microcytic 
hypochromic red blood cells. Anemia affects individuals of all ages but pregnant women 
and preschool-age children have the highest prevalence in the population.100 Anemia 
can negatively affect a child’s cognitive and physical development, and in pregnant 
women anemia has been associated with reduced size and birth weight and increased 
risk of maternal and child mortality.101,102 Across populations, anemia is linked to fatigue 
and poor productivity leading to economic losses.103  
  Another cause of anemia is due to chronic disease or inflammation, which is 
estimated to be the second leading cause of anemia behind iron deficiency.104 During an 
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infection or inflammatory state, the innate immune system triggers an acute phase 
response, sequestering iron within tissues and limiting absorption from the diet resulting 
in hypoferremia. This intricate system of nutrient maneuverability is referred to as 
nutritional immunity, which is designed to protect the host by starving the pathogen and 
limiting virulence.105,106 However, in certain chronic conditions such as cancer, chronic 
kidney disease, and obesity, this response is prolonged due to consistently elevated 
levels of inflammation leading to chronic hypoferremia, severely disrupting systemic iron 
homeostasis. Over time this can lead to anemia of chronic disease (ACD), which is also 
referred to as anemia of inflammation. Clinically, ACD is diagnosed as a normochromic 
normocytic anemia, with reduced serum iron, normal or increased serum ferritin, and 
elevated cytokine levels.86,104 Commonly, due to the more severe underlying cause of 
chronic inflammation, ACD often goes unrecognized and untreated which can negatively 
affect the quality of life, recovery, or even survival of patients. The most effective 
treatment of ACD is to treat the underlying disease, however, in some scenarios this is 
not feasible.  
Iron overload conditions are generally due to genetic mutations causing a 
disruption in iron homeostasis. The most common genetic iron overload disorder is 
hereditary hemochromatosis (HH), which can be caused by several different mutations 
involved in the regulation or synthesis of hepcidin or its target protein, FPN1. The most 
prevalent form of HH is type 1 hemochromatosis associated with a mutation in the HFE 
gene, which disrupts the iron sensing pathway involved in regulating hepcidin synthesis. 
This results in decreased hepcidin expression and increased absorption of iron from the 
diet causing iron overload. Type 1 HH affects about 1 million individuals in the United 
states and is most common among those with norther European ancestry (~1/250 
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people).107,108 The mutation(s) in type 2 and 3 HH are in different genes (HJV, HAMP, 
and TFR2), however they result in the same outcome of impaired hepcidin expression 
causing iron accumulation. Type 2 HH is often called juvenile HH due to the earlier onset 
of symptoms compared to type 1, whereas type 3 is classified as an intermediate form. 
Type 2 and type 3 HH are considered rare genetic disorders and the actual incidence is 
unknown.109,110 The classic treatment for HH is phlebotomy to remove excess iron from 
the body. However, recently researchers have developed minihepcidin compounds that 
have shown to be successful in preventing iron overload in hemochromatosis mouse 
models.111 Therefore, minihepcidin treatment could be a supplemental therapy to help 
control HH iron overload disorders. Type 4 HH, commonly called ferroportin disease, is 
extremely rare and is the result of a mutation in FPN1 causing tissue iron accumulation. 
The severity varies between patients, with treatments targeted to the symptoms of the 
individual.112,113  
Physiological Roles of NCOA4-mediated Ferritinophagy 
 NCOA4 was originally identified as an androgen receptor coactivator and has 
been shown to interact with additional nuclear receptors as well such as glucocorticoid, 
vitamin D, thyroid hormone.114 Recently, a new role of NCOA4 in iron metabolism was 
discovered through quantitative proteomics, identifying it as an autophagic cargo carrier 
receptor for the autophagolysosome-mediated turnover of ferritin, i.e., ferritinophagy.52,53 
NCOA4 was shown to be required for ferritin turnover by iron chelation and that NCOA4 
abundance was responsive to iron treatment, increasing with chelation and decreasing 
with supplementation.53 The responsiveness of NCOA4 to iron status was supported in 
developing erythroid cells, demonstrating an inverse relationship with ferritin 
abundance.29 Combined, these studies indicate that NCOA4-meditaed ferritinophagy is 
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upregulated during iron scarcity to increase bioavailable iron, and repressed when iron is 
replete to promote storage and limit free cytosolic iron levels.  
Given the role of NCOA4 in cellular iron balance, researchers addressed the 
contributions of NCOA4-mediated ferritinophagy during erythropoiesis, a physiological 
process involving an exceptionally high level of iron accumulation and consumption by 
cells. In the early stages of development erythroid progenitor cells accumulate iron, 
storing the majority within ferritin, which is subsequently utilized during heme iron 
synthesis.115,116 Two separate groups demonstrated that NCOA4 depletion in human and 
mouse erythroid cell lines results in impaired ferritin iron utilization and 
hemoglobinization.51,117  These findings were confirmed in an erythroid-specific Ncoa4 
knockout murine model, with adult knockout mice exhibiting a mild hypochromic 
microcytic anemia with elevated ferritin protein abundance and iron contents in the bone 
marrow.118  
The systemic knockout of Ncoa4 in mice produces microcytic hypochromic 
anemia despite signs of systemic iron overload.118,119 Recent comparisons between the 
hematological profiles of systemic Ncoa4 knockout and erythroid-specific Ncoa4 
knockout mice revealed a more profound anemia phenotype in the systemic knockout 
model.118 This supports a role of Ncoa4 in a non-erythroid cell type or tissue contributing 
to erythroid iron homeostasis and red cell development. Notably, accumulation of iron in 
the red pulp of the spleen, a major site of RE macrophages and red cell iron recycling, 
by NCOA4 deficiency has been reported.52 Thus, macrophage NCOA4 may play an 
integral role in the recycling process, which provides the majority of iron needed for 






Figure 1.1: Iron-dependent IRE/IRP interactions post-transcriptionally regulate 
genes involved in cellular iron homeostasis. 
Low iron conditions (left) promote the binding of IRPs to IREs in the 5’- and 3’-UTR of 
mRNA transcripts with the aim to increase cellular iron levels. Binding in the 5’-UTR results 
in a translational block, reducing expression of ferritin (storage) and ferroportin (export). 
Conversely, IRP binding in the 3’-UTR stabilizes the transferrin receptor (TFR1) transcript, 
promoting iron uptake by the cell. In high iron conditions (right) IRPs dissociate from the 
IREs in the 5’ UTR, allowing the ribosome access to translate the protein, increasing 
expression of ferritin and ferroportin. IRP dissociation from the 3’-UTR IRE exposes the 
TFR1 transcript to endonucleases leading to mRNA degradation. IRP – iron responsive 
protein; IRE – iron response element; FTH1 – ferritin H subunit; FTL – ferritin L subunit; 
FPN1 – ferroportin 1; TFR1 – transferrin receptor 1. Image adapted from “Mammalian iron 























Figure 1.2: NCOA4-mediated ferritinophagy and regulation of NCOA4 by HERC2.  
Iron is stored with the ferritin complex. During iron deficient conditions (left) cells promote 
NCOA4-mediated ferritinophagy to meet cellular demands. NCOA4 binds ferritin and 
delivers it to a developing autophagosome. Fusion of the autophagosome with the 
lysosome results in the degradation of the ferritin complex and release of the iron core, 
which is subsequently transported to the cytosol for utilization or export. NCOA4 levels 
are regulated by HERC2 in an iron-dependent manner (right). During iron replete 
conditions, NCOA4 interacts with HERC2, targeting it for ubiquitination and proteasomal 
degradation. Decreased NCOA4 expression stabilizes ferritin and promotes iron storage. 
Image adapted from “The Role of NCOA4-Mediated Ferritinophagy in Health and 






































Figure 1.3: General methods of macrophage iron metabolism.  
Macrophages can acquire iron through several different routes and sources. Transferrin-
bound iron (left) is taken up by TfR1-mediated endocytosis. Within the endosome ferric 
iron (Fe³⁺) is reduced to its ferrous form (Fe²⁺) by metalloreductases and transported to 
the cytosol by DMT1. NTBI can be imported directly by ZIP8 and ZIP14 (middle). 
Erythrophagocytosis of senescent red blood cells is the major form of iron acquisition by 
RE macrophages (right, top). Red blood cell digestion results in the release of heme from 
hemoglobin which is translocated to the cytosol by HRG1. HO-1 liberates iron from heme 
which can then be incorporated into the labile iron pool (LIP). When the LIP is in excess, 
the iron chaperone PCBP1 delivers iron to ferritin for storage. Conversely, NCOA4 
mediates ferritin degradation in a process called ferritinophagy, increasing cytosolic iron. 
Iron can be exported from the cell by FPN1 (right, bottom). FPN1 is post-translationally 
regulated by hepcidin. Abbreviations: Tf – transferrin; TfR1 – transferrin receptor 1; DMT1 
– divalent metal transporter 1; ZIP8/14 – Zrt/Irt-like protein 8/14; HRG1 – heme-responsive 
gene 1; HO1 – heme oxygenase-1; PCBP1 – poly(rC)-binding protein 1; NCOA4 – nuclear 
receptor coactivator 4; FPN1 – ferroportin 1. Image adapted from “Iron Regulation: 



































At the cellular level, iron is required for the formation and function of numerous 
metalloproteins. Yet, free iron is redox-active and thus cytotoxic if not properly 
handled.120 A key function of iron is oxygen transport as a component of hemoglobin in 
red blood cells, which comprises approximately two-thirds of the total iron found in the 
body. In humans, erythrocytes turn over every 120 days and thus need to be replaced 
through constant production of new red blood cells.121,122 The large demand for iron by 
erythropoietic cells is primarily met by the recycling of iron from senescent and effete red 
blood cells. Under normal steady-state conditions, the RE macrophages contribute up to 
~90% of the daily iron requirement for red blood cell replenishment.54  
Macrophage-mediated iron recycling is initiated by the engulfment of 
erythrocytes, termed, erythrophagocytosis. Digestive processes begin in the lysosome 
where red cell hemoglobin (Hb) is reduced to heme and subsequently transported to the 
cytosol, where heme oxygenase-1 extracts iron molecules, destined for export by 
ferroportin.78,79,123,124 An individual human erythrocyte contains about 270 million 
molecules of Hb, with each Hb composed of up to four heme iron molecules.125 Thus, 
macrophages must be equipped to handle the large expansion in its iron load after 
erythrophagocytosis. Ferritin, the sole cytosolic iron storage protein in mammals, 
provides cells the capability to handle excess iron by storing the metal in a stable and 
nontoxic form. An induction in ferritin expression by erythrophagocytosis has been 
reported,124 however, how the stored iron is released from ferritin for ferroportin-
mediated export remains poorly understood.   
Ferritin functions as a 24-subunit heteropolymer of ferritin L (FTL) and ferritin H 
(FTH) subunits, which can accommodate up to 4,500 iron atoms. Ferritin expression is 
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post-transcriptionally regulated by the presence of an IRE in the 5’-UTR of its H and L 
transcripts. With elevated cellular iron levels, IRP-IRE binding decreases, enabling the 
translation of ferritin. Conversely, when iron levels are replete, IRP binding creates a 
translational block to prevent the synthesis of new proteins.22 The regulated release of 
iron from this highly stable form of iron storage is through either proteasomal126 or 
lysosomal degradation.127,128 More recently, the involvement of autophagy in the latter 
process has been revealed, giving rise to the term, ferritinophagy. The process of 
ferritinophagy is initiated by the binding of a selective cargo receptor, NCOA4, to iron-
laden ferritin, which leads to the selective autophagy and subsequent lysosomal 
degradation of the NCOA4-ferritin complex.52,53 Notably, NCOA4 only binds to ferritin H 
to initiate ferritinophagy,51 which is also the subunit conferring ferroxidase activity, 
promoting the retention of iron within ferritin in its non-toxic ferric state.129  
In developing erythroid cells, ferritin iron storage has been proposed as an 
intermediate form of iron, between enhanced import, and delivery to the mitochondria for 
heme biosynthesis.115,116 Recently, NCOA4 has been identified to be integral to the 
regulation of ferritin iron storage and heme production during terminal erythroid 
differentiation.51,117 In agreement with these in vitro studies, microcytic hypochromic 
anemia has been observed in systemic and erythroid-specific Ncoa4 knockout 
mice.118,119 A role of NCOA4 in a non-erythroid blood lineage in the regulation of red 
blood cell production has been recently proposed,130 which supports the more profound 
anemia seen by systemic versus erythroid-specific Ncoa4 knockout.118 Notably, systemic 
knockout of Ncoa4 causes iron accumulation in the red pulp of the spleen, a major site 
of RE macrophages.52,119 These suggest a key role of macrophage NCOA4 in red cell 
metabolism and, presumably, organismal iron recycling.   
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A primary innate response to inflammation or infection is hypoferremia, which 
involves elevated hepcidin activity.85,131 This acute-phase response, referred to as 
nutritional immunity, is intended to limit the availability of iron to invasive pathogens by 
sequestration of systemic iron within iron-supplying cells, including hepatocytes, 
enterocytes, and RE macrophages. However, elevated cellular iron may rather promote 
the virulence of intracellular pathogens, such as Salmonella.132,133 Additionally, cellular 
iron accumulation can impose cytotoxic oxidative stress to cells by producing reactive 
oxygen species.134 Notably, macrophages coordinately regulated the genes of iron 
homeostasis towards iron sequestration in response to classical activation by 
inflammation. This includes elevated ferritin135 and repressed ferroportin136 expressions, 
collectively promoting cellular iron retention. Whether NCOA4 expression and 
ferritinophagy serves as a target of nutritional immunity or inflammatory responses 
remains unknown. 
Macrophages contribute to organismal iron homeostasis and produce innate 
immunity through actively regulating its intracellular iron contents. The studies, herein, 
employ J774 murine macrophages, and examine the roles of NCOA4 and ferritin 
regulation during the adaptation of macrophages to changes in cellular iron availability, 
and the processes of iron recycling after erythrophagocytosis. Moreover, the responses 
of macrophage NCOA4 to hepcidin activity and an inflammatory stimulus were 
recapitulated and characterized in vitro. These cell culture experiments revealed 
regulatory roles of macrophage NCOA4 and ferritinophagy, which are integral to both 
cellular and systemic iron homeostasis during (patho)physiological conditions of iron 
recycling, systemic iron overload, infection, and chronic inflammation. 
   
21 
 
MATERIALS AND METHODS 
Cell Culture and Iron Treatments 
J774, clone E, murine macrophages were maintained at sub-confluency and 
cultured in alpha-minimum essential medium (AMEM; HyClone, GE Life Sciences) 
containing 10% fetal bovine serum (FBS; Sigma), 100 U/mL penicillin and 100 μg/mL 
streptomycin (Corning) at 37°C in 5% CO2.  
Cellular iron deficiency was produced by treatment of an iron chelator, 
deferoxamine (DFO; Sigma-Aldrich), to the culture medium at a final concentration of 
100 μM for 18 hours. Iron loading was achieved by supplementing the medium with 100 
μg/mL of ferric ammonium citrate (FAC; Sigma-Aldrich). 
Erythrocyte Treatment for Erythrophagocytosis by Macrophages 
I adopted a protocol to recapitulate the process of erythrophagocytosis and red 
cell iron recycling using J774 cells, in vitro. Sheep erythrocytes (HemoStat Laboratories) 
were opsonized by incubation with rabbit anti-sheep IgG (MP Biomedicals) at 550 μg of 
IgG per 250 x 106 erythrocytes at 37°C for 20 minutes. Opsonized erythrocytes were 
added to the J774 monolayer (~60% confluency) at an erythrocyte:macrophage ratio of 
10:1, which was considered 0-hour. After 1.5 hours of incubation, cells were washed 
with water to remove noningested erythrocytes by hypotonic lysis. Following two 
additional washes with 1X PBS, cells were incubated in fresh growth medium until 
harvest at the designated times to assess red cell digestion and iron recycling.  
Hepcidin Mimic (PR73) and LPS Treatments 
PR73, a synthetic minihepcidn analog, from Drs. Ganz and Nemeth (UCLA) was 
used to assess the impact of hepcidin activity on our study model. PR73 mimics the 
biological effects of hepcidin by blocking the flux of iron through ferroportin.137 However, 
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it is considerably more stable compared to natural hepcidin, making it suitable for cell 
culture experiments.138 The stock was prepared in DMSO, thus DMSO was added as a 
carrier control. Macrophages not undergoing red cell digestion were treated with 1 μM 
PR73 for 24 hours. Considering the elevated ferroportin expression after 
erythrophagocytosis,124 erythrocyte-laden macrophages were treated with a higher dose 
of 4 μM PR73. For experiments involving erythrophagocytosis, PR73 was added to cell 
culture 4 hours after red cell treatments.   
To study classically activated macrophages in vitro, J774 cells were treated with 
lipopolysaccharide (LPS) as a model of endotoxemia. LPS (Sigma-Aldrich) was added to 
the growth medium at a concentration of 1.0 μg/mL for a duration of 24 hours prior to 
harvest.  
Gene Silencing by siRNA Transfection 
Gene silencing was achieved by liposome mediated delivery of siRNA using 
HiPerFect transfection reagent (Qiagen). J774 cells were seeded and treated with 
mixtures of siRNA and transfection reagent, 24 hours prior to any cell treatment. Cells 
were seeded at a density to maintain sub-confluency throughout experiments. Control or 
NCOA4 siRNA (Silencer Select; Ambion) diluted in Opti-MEM (Invitrogen) were mixed 
with HiPerFect (Qiagen) and added to cells. Following 6 hours of incubation, fresh 
growth medium was added to the transfected cells for subsequent incubation. Final 
siRNA concentrations were at 50 nM per well or culture dish.   
RNA Isolation, Reverse Transcription, and qPCR  
Relative abundance of mRNA transcripts was assessed by qPCR. Cells were 
harvested and treated with TRI Reagent (Sigma-Aldrich) for RNA isolation. Total RNA 
was extracted using the TRI Reagent manufacturer’s protocol. Equal amounts of RNA 
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were reversed transcribed to cDNA using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). qPCR was performed using PowerUp SYBR 
Green Master Mix (Applied Biosystems) with amplifications detected using the CFX 
Connect Real-Time System (Bio-Rad). CFX Connect Software was used to assess the 
melt curve analysis to confirm reaction specificity and set the Cq threshold. qPCR data 
was processed by the ΔΔCq method with Actb or Tbp as housekeeping genes for 
normalization. 
Protein Extraction and Western Blot Analysis 
Cell protein extract was prepared using an NP-40 based lysis buffer [100 mM 
Tris-HCl (pH 7.5), 50 mM KCl, 0.1% NP40, 5.0% glycerol, water, and protease inhibitor 
cocktail (Roche)]. Following centrifugation, the supernatant was collected, and protein 
concentrations were determined using the Pierce BCA Protein Assay kit (Thermo 
Scientific).  
For western blot analyses, equal amounts of protein were mixed with Laemmli 
buffer (Bio-Rad) and a reducing agent, 2-mercaptoethanol (Sigma), and boiled for 10 
minutes. Proteins were separated by electrophoresis on a Mini-PROTEAN TGX 4-20% 
polyacrylamide precast gel (Bio-Rad). Proteins were then transferred to a nitrocellulose 
membrane using the Trans-Blot Turbo Transfer System (Bio-Rad) and RTA Transfer kit 
(Bio-Rad). Protein transfer was confirmed by Ponceau staining. Membranes were 
blocked with a 5% nonfat milk-PBS solution. Primary antibodies were prepared in 5% 
nonfat milk-PBS-T and the following dilutions were used to detect each protein of 
interest: rabbit anti-ferritin at 1:1000 (Sigma-Aldrich, F5012); anti-GAPDH 1:2000 (Bio-
Rad, Cat# 12004167); rabbit anti-NCOA4 at 1:1000 (Bethyl Laboratories, Cat# A302-
272A); and rabbit anti-IRP2 at 1:1000 (Dr. Betty Liebold, University of Utah). Following 
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primary incubation, proteins were visualized and quantified with IRDye anti-rabbit 
secondary antibodies (1:10,000; LI-COR) using a LI-COR Odyssey FC imager system.  
Cell Viability Assay (CCK-8) 
 The Cell Counting Kit-8 (CCK-8; Sigma) assay is a colorimetric method to assess 
the number of viable cells based on cellular dehydrogenase activity. J774 cells were 
plated in a 96-well plate at a density of 2000 cells/well and transfected as described 
above in a total well volume of 100 μL. Following 24 hours of incubation, cells had 
reached a sub-confluent monolayer and DFO (100 μM) was added to the medium and 
allowed to incubate for a total of 18 hours. Two hours prior to measuring the 
absorbance, 10 μL of CCK-8 solution was added to each well. Control wells were 
prepared without cells as a background correction for cell culture medium. The 
absorbance was measured at 450 nm and cell viability was determined as percentage of 
control. 
Measures of Total Cellular and Heme Iron Contents 
Total cellular mineral contents were measured using inductively coupled plasma 
mass spectrometry (ICP-MS) by Dr. Jaekwon Lee at the University of Nebraska. Cells 
were washed twice with PBS supplemented 10 mM EDTA to remove metals non-
specifically bound to cell membranes. Acid-washed tubes were used to prevent 
contamination by external metal sources. Cells were pelleted at 130 x g at 4°C for 10 
minutes and submitted for ICP-MS. Cellular metal contents were normalized to total 
protein contents determined by BCA assays (Thermo Scientific).  
For heme assays, cell protein extract was prepared by solubilizing macrophages 
in Triton X-100 based lysis buffer [20 mM Tris-HCl (pH 7.5), 40 mM KCl, 0.5% Triton X-
100, and water]. Heme contents were colorimetrically measured using the QuantiChrom 
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Heme Assay Kit (BioAssay Systems) following the manufacturers protocol. Absorbance 
at 400 nm was measured using a plate reader and normalized to total protein contents. 
Preparation of Splenic Tissue 
Frozen spleen samples from LPS treated and control (PBS) mice were from Dr. 
Xiaoli Chen’s lab (University of Minnesota). Sixteen-week old, male C57/BL6 mice were 
intraperitoneally injected with 0.3 mg/kg PBS or LPS. The spleen was harvested 6 hours 
after LPS injection, and snap-frozen until processing. For RNA isolation, spleen tissues 
were homogenized in TRI Reagent. After centrifugation to remove residual tissue debris, 
the supernatant was collected for RNA isolation as described above. 
Statistical Analyses 
Cell culture experimental values are presented as mean ± SD. Splenic transcript 
abundance from in vivo experiments are presented as mean ± SEM. n numbers are 
detailed in the figure legends. Comparisons between two groups were performed using 
Student’s t-test. When comparing more than two groups of the same variable, one-way 
ANOVA with a Tukey’s post-hoc test was used. Experiments with multiple independent 
variables were compared by two-way ANOVA with a Tukey’s post-hoc test. For all 
analyses statistical significance was set at *P < 0.05, 2-sided. Statistical analyses were 






Table 1.1: qPCR Primer Sequences.  
Transcript Primer Sequence 
Ncoa4 Ncoa4 forward 5' – AGCTAAGGCACCCAAGGCTA – 3’ 
Ncoa4 reverse 5' – CTTAGGGCCTCCTTTGCACG – 3’  
Tfrc Tfrc forward 5’ – TCACTTCCTGTCGCCCTATGT – 3’  
Tfrc reverse 5’ – AGAGTGTGAGAGCCAGAGCC – 3’  
Fth1 Fth1 forward 5’ – CCACGTGACCAACTTACGCA – 3’  
Fth1 reverse 5’ – TCTCATCACCGTGTCCCAGG – 3’  
Ftl1 Ftl1 forward 5’ – GGAGCGTCTCCTCGAGTTTC – 3’  
Ftl1 reverse 5’ – GAGATGGCTTCTGCACATCCT – 3’ 
Fpn1 Fpn1 forward 5’ – CCCATAGTCTCTGTCAGCCTGC – 3’  
Fpn1 reverse 5’ – CCGTCAAATCAAAG GACCAAA – 3’  
Hmox1 Hmox1 forward 5’ – TGGTGCAAGAT ACTGCCCCT – 3’  
Hmox1 reverse 5’ – GTCTGGGATGAGGTAGTGCTGAT – 3’  
IL6 IL6 forward 5’ – CTCGGCAAACCTACTGCGTT – 3’  
IL6 reverse 5’ – TGACCACAGTGAGGAATGTCCA – 3’  
Actb Actb forward 5’ – AGGAGTACGATGAGTCCGGC – 3’  
Actb reverse 5’ – AGCTCAGTAACAGTCCGCCT – 3’  
Tbp Tbp forward 5’ – AGTTGTGCAGAAGTTGGGCT – 3’  
Tbp reverse 5’ – TACTGAACTGCTGGTGGGTCA – 3’  




Post-transcriptional regulation of NCOA4 in J774 macrophages. 
In prototypic mammalian and erythroid cell culture models, NCOA4 is highly 
responsive to cellular iron status at the protein level.51,117 However, whether NCOA4 is 
regulated by iron in macrophages remain unknown. Thus, I first assessed if NCOA4 is 
responsive to cellular iron status in J774 murine macrophages. Cellular iron overload by 
FAC (100 μg/mL) resulted in markedly increased ferritin protein abundance while 
repressing NCOA4 (Figure 2.1). Conversely, iron deficiency by DFO (100 μM), increased 
NCOA4 abundance with a concomitant decrease in ferritin protein abundance. These 
findings demonstrate an inverse relationship between NCOA4 and ferritin expression in 
J774 macrophages. Notably, the transcript abundance of Ncoa4 was not affected by 
either iron treatment, indicating a post-translational mechanism for regulation (Figure 
2.2). Tfrc abundance confirmed the effectiveness of each iron treatment and 
demonstrate an active IRP/IRE system in macrophages (Figure 2.2). These findings 
indicate that NCOA4 is actively regulated by iron status in macrophages and that 
regulated ferritinophagy may serve as a potential mechanism for controlling 
macrophagic iron storage and homeostasis.  
NCOA4-dependent ferritin regulation in J774 macrophages. 
 To determine the role of NCOA4 in ferritin regulation and macrophage iron 
homeostasis, NCOA4 was knocked down by siRNA transfection. The siRNA-mediated 
gene silencing of NCOA4 was confirmed by repression in both protein and transcript 
abundance versus control levels (Figure 2.3A,B). The loss of NCOA4 produced an 
increase in ferritin protein abundance that was on average 2.5-folds greater than control 
(Figure 2.4). A decrease in IRP/IRE complexes can lead to enhanced translation of 
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ferritin.48,50 NCOA4 deficiency had a minimal impact on IPR2 protein abundance and Tfrc 
mRNA expression, a known target of IRP-mediated regulation (Figure 2.5A,B). These 
identify NCOA4 as a key regulator of ferritin turnover and iron storage in macrophages.  
NCOA4-dependent ferritin turnover and survival of iron-deficient macrophages.  
 The marked increase in NCOA4 expression by iron deprivation and its role in 
ferritin degradation suggests its involvement in the adaptation of macrophages to cellular 
iron restriction. To test this, J774 cells were treated with NCOA4 siRNA and DFO to 
restrict ferritin turnover and cellular iron import, respectively. By NCOA4 depletion, 
ferritin accumulation occurred in both iron-adequate and DFO-treated cells (Figure 2.6). 
The repression in ferritin by DFO was present in both control and NCOA4 siRNA-treated 
cells (Figure 2.6), likely mediated by increased IRP activity (Figure 2.7A,B). Yet, the 
ferritin levels of DFO-treated NCOA4-deficient cells were comparable to iron-adequate 
control cells, indicating less supply of iron from both storage and import (Figure 2.6).  
 Iron is essential for cell survival and growth.139 Thus, the impact of limiting iron 
from the extracellular (import) and intracellular (ferritin) sources was assessed by the 
CCK-8 cell viability assay. The number of viable cells was significantly reduced by DFO-
induced iron chelation only when J774 cells were NCOA4-deficient (Figure 2.8). Notably, 
DFO treatment or NCOA4 deficiency alone did not significantly influence cell viability or 
growth. These identify NCOA4-dependent turnover of ferritin as an essential mechanism 
for macrophages to adapt to cellular iron deficiency, and ferritin as an alternative source 




Cellular heme and non-heme iron contents in macrophages after 
erythrophagocytosis. 
A primary role of macrophages in systemic iron homeostasis is in the recycling of 
iron from effete and senescent red blood cells. This process requires the conversion of 
heme iron from ingested red cells to elemental iron by macrophages.54 To assess the 
potential role of NCOA4 in iron handling during this process, J774 cells were treated with 
opsonized erythrocytes to induce erythrophagocytosis.124 
After 3 hours of red cell treatment, J774 cells featured a red coloration, indicative 
of the cellular ingestion of erythrocytes (Figure 2.9). This was confirmed by an acute 
increase in macrophage heme and total iron contents after 4 hours of red cell treatments 
(Figures 2.10A and 2.11). Heme oxygenase-1 (Hmox1) mediates heme digestion, with 
gene expression upregulated by elevated cellular heme contents.79,124 Hmox1 mRNA 
levels peaked 3 hours after erythrophagocytosis (Figure 2.10B), which preceded heme 
digestion evidenced by the disappearance of the red coloration of erythrocyte-treated 
macrophages (Figure 2.9). Cellular heme contents returned to the basal levels after 12 
hours (Figure 2.10A). Despite the disappearance of heme, macrophage iron content 
remained elevated at 12 hours, indicating the cellular retention of digested iron in a non-
heme iron form (Figure 2.11). 
Ferritin accumulation and NCOA4-mediated ferritin turnover after 
erythrophagocytosis. 
Accumulation of non-heme iron in cells is expected to result in increased iron 
storage within ferritin. Thus, I measured the temporal pattern of ferritin expression over 
24 hours after erythrophagocytosis. Ferritin protein abundance gradually increased until 
12 hours of erythrophagocytosis, and subsequently decreased at 24 hours (Figure 2.12). 
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No change was seen in ferritin transcript abundance (Fth1, Ftl1; Figure 2.13). Thus, the 
changes in ferritin protein levels after erythrophagocytosis are due to post-transcriptional 
regulation. IRP2 protein and Tfrc mRNA featured a transient decline 3-4 hours after red 
cell ingestion, indicating an expansion in the cytosolic labile iron pool (Figure 2.14). By 
12 hours IRP2 and Tfrc returned to near-basal levels. These indicate that macrophages 
transiently increase ferritin expression to handle the expansion in the cytosolic non-
heme iron contents prior to export by ferroportin activity.124  
Notably, between 12 and 24 hours after erythrophagocytosis, when both 
macrophage iron and ferritin levels declined, a moderate increase in NCOA4 abundance 
was identified (Figures 2.11, 2.15). To test whether NCOA4 plays a role in the regulation 
of macrophage ferritin at the later stages of iron handling after erythrophagocytosis, 
J774 cells were treated with NCOA4 siRNA and then with opsonized erythrocytes. The 
loss of NCOA4 by siRNA transfection was confirmed by a repression in protein 
abundance (Figure 2.16). Both control and NCOA4 siRNA-treated cells demonstrated an 
increase in ferritin abundance at 12 hours after erythrophagocytosis. However, the 
decrease in ferritin at 24 hours was lost when cells were lacking adequate NCOA4 
(Figure 2.16). These demonstrate that NCOA4 mediates the turnover of ferritin in the 
late stages of red cell iron recycling by macrophages.  
Repression of NCOA4 by hepcidin activity in macrophages. 
Cellular iron export by macrophages is a target of hepcidin due to their role in 
systemic iron metabolism and innate immunity.124,140 Hepcidin limits the flux of 
macrophage iron into the bloodstream by blocking ferroportin activity and causing 
retention of iron within macrophages.81,141 To assess the potential role of NCOA4 in 
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macrophage iron regulation by hepcidin, J774 cells were treated with a synthetic 
minihepcidin analog, PR73.137    
Hepcidin activity repressed NCOA4 abundance with a concomitant increase in 
ferritin protein abundance (Figure 2.17A). Ncoa4 transcript abundance was unaffected 
by hepcidin activity, indicating a post-transcriptional regulatory mechanism (Figure 
2.17B). Notably, IRP2 protein and Tfrc mRNA abundance were not affected by PR73 
(Figure 2.18A,B). These suggest that less NCOA4 expression and ferritinophagy may 
facilitate the adaptation of macrophages to cellular iron accumulation by hepcidin 
activity. To test this, I artificially repressed NCOA4 by siRNA transfection in J774 cells 
and assessed if ferritin is further enhanced by PR73. The loss of NCOA4 produced an 
increase in ferritin abundance compared to control levels (Figure 2.19, −Hepcidin). 
Interestingly, the increase in ferritin abundance produced by PR73 was lost in NCOA4-
depleted cells (Figure 2.19), indicating that the expansion in ferritin expression by 
NCOA4 depletion was sufficient for handling the increase in cellular iron by hepcidin 
activity. Additionally, no change in IRP2 abundance was observed by hepcidin activity in 
either siRNA treatment group (Figure 2.19).  
To test the hepcidin effect in macrophages undergoing red cell iron recycling, 
J774 cells were first treated with opsonized erythrocytes and then PR73. Hepcidin 
activity by PR73 repressed NCOA4 abundance 24 hours after erythrophagocytosis and 
prevented the drop in ferritin abundance between 12 and 24 hours (Figure 2.20). 
Hepcidin activity had no effect on IRP2 abundance after 24 hours of erythrophagocytosis 
(Figure 2.21). To further confirm whether the repression of NCOA4 by PR73 is mediating 
the ferritin responses, the effects of PR73 on ferritin in erythrocyte-treated control and 
NCOA4-deficient J774 cells were compared. After 24 hours of erythrophagocytosis, 
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NCOA4-deficient macrophages produced more ferritin when PR73 was not present 
(Figure 2.22, −Hepcidin). However, the effect of NCOA4 deficiency was absent when 
cells were treated with PR73 (Figure 2.22, +Hepcidin). In other words, NCOA4 
repression by siRNA was sufficient to reproduce the effects of PR73 on ferritin 
expression. These identify the accumulation of ferritin by a repression in NCOA4 as a 
mechanism to sequester excess cytosolic iron by hepcidin activity in macrophages. 
NCOA4 repression in macrophages activated by LPS. 
Macrophages are intimately tied to innate immunity.106 Classical activation 
towards inflammatory M1 macrophages involve coordinated regulation of iron genes 
leading to cellular iron sequestration.135,136,142 Thus, to test whether NCOA4 is involved in 
this response, J774 cells were activated by LPS and NCOA4 expression was assessed. 
LPS repressed NCOA4 on the transcript and protein levels (Figure 2.23A,B). 
Additionally, ferritin protein abundance increased by LPS, with the lower band of the 
ferritin doublet producing a particularly pronounced response (Figure 2.24A). An 
increase in ferritin expression by LPS was measurable at the transcript level, with a 2.5-
fold upregulation of ferritin H (Fth1) mRNA. However, LPS had no effect on ferritin L 
(Ftl1) transcript levels (Figure 2.24B). LPS-mediated activation of J774 cells was 
confirmed by a dramatic increase in IL6 mRNA143,144 (Figure 2.25). This was further 
supported by a repression in Fpn1 mRNA, which has been previously characterized as a 
response of activated macrophages (Figure 2.23B).136,145 These identify a repression in 
NCOA4 as a part of the coordinated regulation of iron genes by inflammation or infection 
to sequester iron within macrophages. Notably, the response of Ncoa4 was measurable 
at the mRNA level, which is distinct from the post-translational mechanism for NCOA4 
regulation by iron status.29,51  
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Downregulation of splenic NCOA4 by LPS-induced endotoxemia in mice. 
The spleen is the primary tissue of RE macrophage-mediated iron recycling.54 To 
determine if inflammation produces a similar repression of NCOA4 in vivo, Ncoa4 mRNA 
in splenic tissue of mice with LPS-induced endotoxemia were measured. Splenic Ncoa4 
mRNA was repressed by nearly 40% in LPS-treated mice compared to PBS-injected 
controls (Figure 2.26). Similar to the expression pattern of J774 cells, ferritin H (Fth1) 
abundance increased by 2.5-fold, whereas ferritin L (Ftl1) abundance slightly decreased 
by LPS (Figure 2.26). As expected, Fpn1 mRNA was repressed, along with a marked 
increase in IL6 mRNA, indicating the effective stimulation of an inflammatory response 
by LPS in vivo (Figure 2.26). These findings reinforce the immunological implications of 
the in vitro LPS studies, and further support the role of NCOA4 in regulating 
















Figure 2.1: Macrophage NCOA4 responds to iron status demonstrating an inverse 
expression pattern with ferritin abundance.  
Iron overload by FAC (100 μg/mL; 18 hours) repressed NCOA4 and increased ferritin 
abundance in J774 cells. Conversely, by DFO-mediated iron chelation (100 μM; 18 




















Figure 2.2: Transferrin receptor (Tfrc) mRNA responds to iron treatment, whereas 
Ncoa4 mRNA is unchanged.  
J774 cells were treated as described in Figure 2.1. Transcript abundance was measured 
by qPCR and normalized by Tbp; n = 3 independent experiments. ***P < 0.001 vs 





































Figure 2.3: Macrophage NCOA4 is effectively knocked down by siRNA 
transfection.  
(A) Western analysis demonstrates repressed NCOA4 abundance by siRNA 
transfection. (B) A significant repression in Ncoa4 mRNA confirms an effective 
knockdown. Total siRNA treatment time was 42 hours. qPCR samples are normalized to 



















































Figure 2.4: The loss of NCOA4 results in an accumulation of ferritin. 
Ferritin protein abundance significantly increases by the loss of NCOA4. Ferritin 
abundance is normalized to GAPDH; n = 5 from 4 independent experiments. ***P < 




















































Figure 2.5: NCOA4 depletion has no effect on cellular iron status markers. 
IRP2 (A) and Tfrc (B) abundance are minimally affected by the loss of NCOA4. IRP2 
abundance is normalized to GAPDH; n = 3 from 3 independent experiments. Tfrc is 
normalized to Tbp; n = 4 from 4 independent experiments. P value measured by 2-tailed 




















































Figure 2.6: The depletion of NCOA4 impairs ferritin turnover during iron 
restriction. 
Ferritin degradation is impaired in NCOA4-depleted cells under iron adequate and iron 
restricted conditions. Cells were transfected with siRNA 24 hours prior to DFO (100 μM, 
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Figure 2.7: Cellular iron markers are unaffected by the loss of NCOA4 in iron 
deficient conditions.  
(A) Iron restriction by DFO increases IRP2 abundance (A) and Tfrc mRNA (B) in both 
control and NCOA4-deficient cells. Cells were treated as described in Figure 2.6. Tfrc is 
normalized to Tbp; n = 3 from 3 independent experiments. **P < 0.01 by 2-way ANOVA 
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Figure 2.8: The loss of NCOA4 combined with iron restriction reduces the number 
of viable cells compared to controls, measured by CCK-8 assay. 
Restricting iron from both extracellular (DFO) and intracellular (NCOA4 siRNA) iron 
sources reduces the number of viable cells compared to control conditions (control 
siRNA). NCOA4 depletion or DFO treatment alone did not affect cell viability. Cells were 
treated as described in Figure 2.6. n = 4 biological replicates. *P < 0.05 vs Control 

















































Figure 2.9: Changes in cell pellet color after erythrophagocytosis.  
Red cell treatment (+RBC) produces a pronounced red cell pellet color that gradually 
disappears by 12 h. Macrophages were fed opsonized red blood cells (10:1 
erythrocyte:macrophage) for 1.5 hours and harvested at the indicated time points. 













































Figure 2.10: Erythrophagocytosis acutely increases macrophage heme contents 
and Hmox1 expression.  
Macrophage heme content (A) and heme oxygenase-1 (Hmox1) expression (B) 
significantly increase after erythrophagocytosis, with both returning to near basal levels 
by 12 h. Cells were treated as described in Figure 2.9. Heme content is normalized to 
total cellular protein; n = 4 biological replicates. Hmox1 is normalized to Actb; n = 3 






























































Figure 2.11: Macrophage iron content dramatically changes throughout red cell 
iron recycling.  
Erythrophagocytosis significantly increases cellular iron content with a steady decline 
thereafter. Cells were treated as described in Figure 2.9. Cellular iron content was 
measured by ICP-MS and normalized to total cellular protein; n = 4 biological replicates. 





































































Figure 2.12: Ferritin protein abundance peaks 12 h after erythrophagocytosis.  
Ferritin protein increases following red cell ingestion, peaking at 12 h with a subsequent 
decrease by 24 h. Cells were treated with red cells as described in Figure 2.9. Ferritin 
abundance is normalized to GAPDH; n = 6 from 3 independent experiments. Different 

































































Figure 2.13: Erythrophagocytosis and iron recycling has no effect on ferritin 
transcript abundance.  
Ferritin H (Fth1) and L (Ftl1) mRNA abundance is consistent throughout red cell iron 
recycling. Cells were treated with opsonized red cells as described in Figure 2.9. Fth1 
and Ftl1 are normalized to Actb; n = 3 biological replicates. Statistical significance was 























































Figure 2.14: Erythrophagocytosis decreases IRP2 protein and Tfrc mRNA 
abundance in macrophages.  
IRP2 abundance (A) and Tfrc mRNA (B) are repressed following red cell ingestion. Both 
markers return to basal levels by 12 h. Cells were treated with opsonized red cells as 
described in Figure 2.9.Tfrc is normalized to Actb; n = 3 biological replicates. *P < 0.05 






































Figure 2.15: NCOA4 increases in the late stages of iron recycling by macrophages. 
The decrease in ferritin between 12 and 24 h is seen with a concomitant increase in 
NCOA4 abundance. Macrophages were treated with opsonized red cells as described in 








































Figure 2.16: The loss of NCOA4 prevents the turnover of ferritin between 12 and 
24 hours. 
The decrease in ferritin abundance between 12 and 24 h (Control siRNA) is lost by 
NCOA4 depletion. Cells were transfected 24 hours prior to erythrophagocytosis. Ferritin 
is normalized to GAPDH; n = 3 from 3 independent experiments. **P < 0.01 vs Control 
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Figure 2.17: Hepcidin activity represses NCOA4and increases ferritin protein 
abundance in macrophages. 
(A) Hepcidin activity (1 μM; 24 hours) significantly decreases NCOA4 abundance 
resulting in an accumulation of ferritin. (B) Ncoa4 mRNA does not change by hepcidin 
activity. NCOA4 and ferritin are normalized to GAPDH; NCOA4 n = 3 from 3 
independent experiments; ferritin n = 5 from 3 independent experiments. Ncoa4 is 
normalized to Tbp; n = 3 from 3 independent experiments. Statistical significance was 







































































Figure 2.18: Markers of cellular iron status are unaffected by hepcidin activity. 
IRP2 protein (A) and Tfrc mRNA (B) abundance are unchanged by hepcidin activity (1 
μM; 24 hours). IRP2 is normalized to GAPDH; n = 3 biological replicates. Tfrc is 
normalized to Tbp; n = 3 from 3 independent experiments. Statistical significance was 
determined by 2-tailed t test. 
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Figure 2.19: Artificially repressing NCOA4 negates the increase in ferritin by 
hepcidin.  
No significant difference was seen in ferritin abundance by hepcidin in NCOA4-deficient 
macrophages. Additionally, hepcidin does not affect IRP2 expression in Control and 
NCOA4 siRNA treated macrophages. Macrophages were transfected with siRNA 24 
hours prior to hepcidin treatment (1 μM; 24 hours). Ferritin is normalized to GAPDH; n = 
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Figure 2.20: Hepcidin activity prevents the turnover of ferritin in the late stages of 
red cell iron recycling.  
Hepcidin represses NCOA4 and abolishes the drop in ferritin between 12 and 24 h. J774 
cells were fed opsonized red cells to induce erythrophagocytosis and subsequently 
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Figure 2.21: IRP2 abundance is unchanged by hepcidin activity at 24 hours of red 
cell iron recycling. 
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Figure 2.22: The loss of NCOA4 represses the magnitude of the ferritin response 
to hepcidin at 24 hours of red cell iron recycling.  
Macrophages were transfected with siRNA 24 hours prior to erythrophagocytosis and 
PR73 (4 μM) treatment.  
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Figure 2.23: LPS represses NCOA4 and Fpn1 in macrophages. 
(A) NCOA4 protein abundance is decreased by LPS (1 μg/mL, 24 hours). (B) LPS 
treatment significantly represses Ncoa4 and Fpn1 transcript abundance.  Ncoa4 and 
Fpn1 are normalized to Actb; n = 3 independent experiments. *P < 0.05; **P < 0.01, 2-























































Figure 2.24: LPS activation promotes ferritin iron storage in macrophages.  
(A) Ferritin protein abundance increases by LPS treatment (1 μg/mL; 24 hours). (B) 
Ferritin H (Fth1) transcript increases by LPS, however ferritin L (Ftl1) does not change. 
Ferritin protein is normalized to GAPDH; n = 3 biological replicates. Fth1 and Ftl1 are 






























































Figure 2.25: LPS treatment elicits an inflammatory response in J774 macrophages. 
IL6 transcript dramatically increases in response to LPS in macrophages. Cells were 
treated with LPS (1 μg/mL) for 24 hours. IL6 is normalized to Actb; n = 3 biological 
















































Figure 2.26: Endotoxemia by LPS represses splenic Ncoa4, in vivo.  
Differential expression of splenic inflammatory and iron regulatory genes by LPS 
administration. Mice were treated with 0.3 mg/kg LPS or PBS (control) via intraperitoneal 
injection 6 hours prior to harvest. All genes are normalized to Tbp; n = 5 control; n = 9 



































































Iron is required for numerous metabolic processes. Yet, mishandled cellular iron 
can be cytotoxic.120 Thus, coordinated cellular mechanisms adapt to iron fluctuations and 
cellular demands to maintain homeostasis and proper functioning. Cellular iron 
homeostasis is maintained by balancing iron import, utilization, storage, and export, 
which is largely mediated by the IRP/IRE regulatory system. The targets of this 
regulation include the iron importer genes TfR1 and DMT1, iron exporter ferroportin, and 
the cytosolic iron storage complex ferritin.31,33,48,146,147 Iron storage within ferritin is a 
crucial component of the cells capacity to prevent cellular iron overload and toxicity.148,149 
Recently, NCOA4 has been characterized as the selective cargo receptor for autophagy-
mediated release of iron from ferritin, termed, ferritinophagy. NCOA4 initiates 
ferritinophagy by binding to ferritin, which is subsequently degraded via the 
lysosome.52,53 Notably, cellular iron restriction can enhance NCOA4 expression, which 
promotes the liberation of stored iron from ferritin.29,53 Macrophages are multifunctional 
cells, which carry out central roles in systemic iron homeostasis and innate immunity.150 
The current studies, employing J774 macrophages, demonstrate an essential role of 
NCOA4-mediated ferritinophagy in macrophage iron homeostasis, and its regulation by 
cellular iron status. Moreover, the present studies determined the roles of NCOA4 in 
ferritin regulation after erythrophagocytosis and by systemic cues of iron overload and 
inflammation by hepcidin activity and LPS. 
Reticuloendothelial macrophages are critical to systemic iron homeostasis due to 
their role in recycling iron from effete red cells, a process that provides over 90% of the 
daily iron requirement for new red cell production.54 Red blood cells contain vast 
amounts of iron as a component of heme, therefore red cell digestion and iron recycling 
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would involve acute expansion in the cellular iron contents of erythrophagocytosing 
macrophages. The current studies identify a transitional storage of iron within ferritin 
between heme digestion and the export of elemental iron by ferroportin. This is 
remarkably similar to the role of ferritin during terminal erythroid development, where it 
functions as an intermediate form of iron between iron import and mitochondrial heme 
biosynthesis.51,117 At the later stages of erythroid differentiation, NCOA4 is highly 
upregulated and mediates the release of stored iron towards the mitochondria.51,117 The 
results from the present studies reveal a similar role of NCOA4 in macrophages, 
mediating a directional flux of intracellular iron, but rather from red cell heme digestion 
towards the exporter, ferroportin. Notably, recent Ncoa4 knockout mouse models have 
demonstrated the contribution of non-erythroid NCOA4 to the maintenance of 
erythropoiesis.118,130  Additionally, the accumulation of splenic iron has been associated 
with microcytic anemia by systemic and bone-marrow-specific losses of Ncoa4 in 
mice,118,119,130 proposing a role of NCOA4 in RE macrophage iron recycling. This would 
suggest that NCOA4 is essential to erythropoiesis not only during red cell development, 
but also during the recycling of iron back to the erythron by RE macrophages. 
Similar to cellular iron balance, organismal iron distribution and homeostasis is 
regulated through an orchestrated control of iron utilization, acquisition, recycling, and 
storage. Central to the regulation of systemic iron homeostasis is the peptide hormone, 
hepcidin. Upregulated by systemic iron overload and inflammation, circulating hepcidin 
targets ferroportin on the plasma membrane of enterocytes, hepatocytes, and RE 
macrophages to decrease ferroportin activity and limit the flux of iron into the blood 
circulatory system.122 However, the retention of cellular iron by hepcidin may impose 
greater oxidative stress due to the redox-active nature of iron. Therefore, due to the loss 
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of exporter activity by hepcidin, expanded iron storage capacity would become the 
primary mechanism to handle excess iron. This would include increased production, 
metalation, and/or fewer losses of ferritin complexes. The present studies demonstrate a 
repression of NCOA4 by hepcidin activity, which reveals repressed ferritinophagy as a 
mechanism to prevent cellular iron overload by hepcidin in macrophages. It was recently 
demonstrated that ferroportin overexpression in HEK293 cells increased ferritin turnover 
in an NCOA4-dependent manner,151 supporting the interaction between ferroportin 
activity and NCOA4-mediated ferritinophagy. Together, these identify a role of NCOA4 in 
mediating the cross-talk between systemic and cellular regulatory mechanisms to 
remove excess iron, by hepcidin and ferritin, respectively.  Of note, is the remarkably 
similar phenotypic characteristics of systemic Ncoa4-knockout mice and mice with 
macrophage-specific ferroportin deletion, both exhibiting mild anemia with tissue ferritin 
and iron accumulation, predominantly in the spleen and liver.118,119,152 The similarities in 
presentation could be representative of the relationship between the two mechanisms.  
The multifunctional capabilities of macrophages is due to their incredible 
plasticity, which allows them to adapt their physiology to a changing environment. In 
response to environmental cues, macrophages are activated to unique polarization 
states with distinct functions and genetic profiles. By inflammation or infection, 
macrophages are considered classically activated, or M1 macrophages.153 This induces 
a coordinated shift in iron metabolism genes to sequester iron within the macrophage as 
a function of nutritional immunity.106 Increased hepcidin activity is also an integral 
element of nutritional immunity. Hepcidin-induced hypoferremia is protective against 
extracellular pathogens, however it produces an iron-rich microenvironment within 
macrophages that is favored by intracellular pathogens, such as Salmonella.106,132,133 
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Therefore, sequestered iron must be properly handled to limit intracellular microbial 
burden and minimize oxidative stress. Separate from the post-translational regulation by 
hepcidin, previous studies have demonstrated a profound repression in ferroportin 
mRNA levels in response to inflammation.136,145,154 Severely limiting cellular iron flux 
would necessitate an increase in ferritin iron storage, which has been demonstrated by 
increased ferritin H expression through enhanced transcription and protein synthesis. 
Interestingly, ferritin L expression is not affected under these conditions.135,155–157 Unlike 
ferritin L, ferritin H possesses ferroxidase activity (converting Fe2+ to Fe3+) which permits 
intracellular iron to be stored in its non-toxic form.129 Moreover, a recent group 
demonstrated that ferritin H is required for iron sequestration by inflammation and 
contributes to macrophage activation.157 The present studies identified repressed Ncoa4 
expression as a mechanism contributing to the iron retention by classically activated M1 
macrophages. This further demonstrates a regulatory role of NCOA4 in altered 
macrophage iron metabolism by inflammation. 
Notably, Ncoa4 has been shown to be necessary for the mobilization of iron 
during an acute increase in iron demand. Compared to wild-type controls, Ncoa4 
knockout mice failed to increase transferrin saturation and serum iron levels following 
administration of erythropoietin.130 Thus, the differences in ferritin H and ferritin L 
expression by inflammation could serve another physiological purpose, which is that 
NCOA4 specifically binds ferritin H for initiating ferritinophagy.51,52 Therefore, ferritin 
complexes predominantly composed of ferritin H subunits would be more efficient 
targets for NCOA4-mediated ferritinophagy once infection or inflammation subsides. 
Importantly, this would provide a more rapid recovery from hypoferremia to restore 
erythropoietic iron demands.   
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NCOA4 has been demonstrated to be post-translationally regulated in an iron-
dependent manner. When cellular iron is replete, HERC2, an E3 ubiquitin ligase, 
mediates the proteasomal degradation of NCOA4 to limit ferritinophagy and promote 
ferritin iron storage. Conversely, when cellular iron is low, NCOA4 is stabilized, 
permitting ferritin binding for lysosomal degradation.29,51 The present studies 
demonstrate macrophage Ncoa4 regulation is predominantly occurring on the protein 
level, supporting HERC2-mediated regulation. However, the LPS-induced repression in 
macrophage and splenic Ncoa4 at the transcript level indicates a regulatory mechanism 
distinct from the HERC2-mediated post-translational mechanism. Of relevance is the 
transcriptional upregulation of Ncoa4 by GATA1 in developing erythroid cells,158 which 
permits promoted ferritinophagy despite elevated cellular iron contents. This novel mode 
of Ncoa4 regulation will require future studies to determine the mechanisms leading to 
the repression in its mRNA.   
Iron disorders and conditions leading to dysregulated iron affects millions of 
people, therefore the search for effective treatments to combat them is constant. The 
present studies have several clinical implications owing to the role of RE macrophages 
in systemic iron homeostasis. The most common genetic disorder leading to iron 
dysregulation is hereditary hemochromatosis (HH).159 There are several types of HH, 
with the most prevalent types characterized by low hepcidin expression leading to 
hyperabsorption of dietary iron, resulting in tissue iron overload. If untreated, HH can 
lead to organ damage, cirrhosis, cardiovascular complications, diabetes mellitus and 
increased risk of infections.159,160 To date, the most common treatment strategy for HH is 
phlebotomy.160 However, more recently, synthetic minihepcidin analogs have begun 
clinical trial testing as a pharmacological strategy to combat HH.161 Due to impaired 
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hepcidin activity by HH, iron flux from RE macrophages is unabated. The current studies 
have identified macrophage NCOA4 and ferritinophagy as an important contributor to 
systemic iron homeostasis. Thus, therapeutic treatments targeting macrophage NCOA4-
mediated ferritinophagy, upstream of ferroportin-mediated export, to limit the cellular iron 
flux could be an effective treatment strategy to combat iron overload by HH. 
Due to advancements in health care and effective treatments of certain diseases, 
survival from chronic health conditions and the presence of chronic inflammation has 
become more prevalent in the population.162 Acute inflammation leads to hypoferremia 
as a host defense mechanism.163 Repeated and prolonged stimulation of this pathway by 
chronic inflammation can lead to anemia of chronic disease (ACD) due to iron-restricted 
erythropoiesis.86 ACD is the second most common form of anemia behind only iron 
deficiency anemia, affecting individuals with chronic infections, autoimmune disorders, 
cancer, chronic kidney disease, and many other chronic conditions.164 It is characterized 
by normocytic or microcytic anemia and tissue iron accumulation. This is remarkably 
similar to the phenotypic presentation of Ncoa4-knockout mice.118,119 The current studies 
demonstrate that inflammation and hepcidin represses NCOA4 and ferritinophagy, 
contributing to tissue iron accumulation. Therefore, potential therapeutic treatments 
could be developed to target ferritinophagy, or NCOA4 specifically, to promote the flux of 
iron from RE macrophages. Additionally, based on the cross-talk between ferritin 
regulation and hepcidin, targeting an increase in ferroportin activity would promote 






 The current studies detail the roles and regulation of NCOA4 and ferritinophagy 
in macrophages, demonstrating significant importance in both cellular and systemic iron 
homeostasis. Specifically, NCOA4 is required for ferritin iron utilization in iron deprived 
conditions. Additionally, macrophage NCOA4 is imperative to the turnover of ferritin in 
the late stages of red cell iron recycling, a process that provides a majority of the iron 
necessary to sustain erythropoiesis. Treatment of macrophages with PR73, a 
minihepcidin analog possessing hepcidin activity, repressed NCOA4-mediated 
ferritinophagy, identifying a cross-talk between systemic and cellular iron homeostatic 
mechanisms. Lastly, macrophage Ncoa4 mRNA was shown to be repressed by LPS-
mediated inflammation likely as a mechanism to promote iron sequestration. This novel 
effect was confirmed in vivo by analyzing the splenic tissue of mice with LPS-induced 
endotoxemia. Further research employing animal models of macrophagic Ncoa4 
knockout would provide new insights on the impact of our findings at the organismal 
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